Genes2me: Financial Breakdown
Decoding financial health metrics of Genes2me
Total Revenue₹21.7 Cr-21%Prev. FY
Total Expenses₹21.6 Cr-21%Prev. FY
Profit After Tax₹-23.1 Lakh-284%Prev. FY
Total Assets₹55.3 Cr9%Prev. FY
Net Profit Margin-1.1%-331%Prev. FY
FAQs on Financials of Genes2me
No. In FY25, Genes2me reported a net loss of ₹23.1 Lakh, so it was not profitable.
Genes2me's revenue declined 20.3% year-on-year, from ₹27.2 Cr in FY24 to ₹21.7 Cr in FY25.
Genes2me's estimated EBITDA for FY25 was ₹1.9 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, Genes2me posted revenue of ₹21.7 Cr (down 20.3% YoY) and a net loss of ₹23.1 Lakh. Explore the full financials of Genes2me here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links